NVS
Novartis AG
NYSEUSDEQUITY
Healthcare
DELAYED
Sell
-26/100
Last price
142.40
▲ 1.47 (1.04%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
140.25
Prev close
140.93
Day high
141.39
Day low
139.67
Volume
1.57M
Market cap
$267.60B
P/E (TTM)
21.27
52W range
121.57 – 170.46
Day trading desk
Gap from prior close
-0.48%
Prior close 140.93
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
1.53%
140.25 – 142.40
Position in range
100%
Near session high
ATR (14D)
2.01
1.41% of price
Prior day high
141.02
PDH
Prior day low
139.31
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 1.96M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.38%
-5.3%
1M
-12.00%
-13.2%
3M
-9.27%
-13.8%
6M
-6.90%
-25.1%
YTD
+2.12%
-12.1%
1Y
+6.34%
-10.1%
3Y
+38.22%
-44.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NVS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
228.09K
Total on file
Fundamentals
Market cap$267.60B
Enterprise value$309.40B
Revenue (TTM)$56.69B
Gross profit$42.51B
EBITDA$23.10B
Net income$12.76B
EPS (TTM)$6.62
Free cash flow$11.90B
Total cash$7.62B
Total debt$49.01B
Book value / share$21.86
Shares outstanding1.90B
Float1.86B
Short % of float0.27%
Dividend yield3.37%
Beta (5Y)0.47
Valuation & profitability ratios
Trailing P/E21.27
Forward P/E14.38
PEG ratio3.30
Price / sales—
Price / book6.44
EV / revenue5.46
EV / EBITDA13.40
Gross margin74.98%
Operating margin34.62%
Profit margin22.50%
Return on equity30.35%
Return on assets10.25%
Debt / equity116.85
Current ratio0.86
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $56.67B | $51.72B | $46.66B | $43.46B | +9.6% |
| Operating revenue | $54.53B | $50.32B | $45.44B | $42.21B | +8.4% |
| Cost of revenue | $13.70B | $12.83B | $12.47B | $11.58B | +6.8% |
| Gross profit | $42.98B | $38.90B | $34.19B | $31.88B | +10.5% |
| Research & development | $11.20B | $10.02B | $11.37B | $9.17B | +11.8% |
| Selling, general & admin | $13.25B | $12.57B | $12.52B | $12.19B | +5.4% |
| Total operating expense | $25.33B | $24.35B | $24.42B | $23.93B | +4.0% |
| Operating income | $17.64B | $14.54B | $9.77B | $7.95B | +21.3% |
| Net interest income | -$980.00M | -$686.00M | -$419.00M | -$574.00M | -42.9% |
| Pre-tax income | $16.35B | $13.64B | $9.12B | $7.18B | +19.9% |
| Tax provision | $2.38B | $1.70B | $551.00M | $1.13B | +40.2% |
| Net income | $13.98B | $11.94B | $14.85B | $6.96B | +17.1% |
| Net income to common | $13.98B | $11.94B | $14.85B | $6.96B | +17.1% |
| Basic EPS | 7.21 | 5.92 | 7.15 | 3.19 | +21.8% |
| Diluted EPS | 7.15 | 5.87 | 7.10 | 3.17 | +21.8% |
| EBIT | $17.50B | $14.65B | $9.98B | $7.98B | +19.5% |
| EBITDA | $22.82B | $20.71B | $18.25B | $14.68B | +10.2% |
| Basic shares | 1.94B | 2.02B | 2.08B | 2.18B | -3.9% |
| Diluted shares | 1.96B | 2.04B | 2.09B | 2.20B | -3.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.44B | $11.46B | $13.39B | $7.52B | — | -0.2% |
| Cash & short-term investments | $11.53B | $13.35B | $13.96B | $18.61B | — | -13.6% |
| Accounts receivable | $8.94B | $7.42B | $7.11B | $8.07B | — | +20.4% |
| Inventory | $6.27B | $5.72B | $5.91B | $7.17B | — | +9.5% |
| Total current assets | $30.46B | $29.70B | $30.48B | $36.91B | — | +2.5% |
| Property, plant & equipment | $12.35B | $10.87B | $10.92B | $12.20B | — | +13.6% |
| Goodwill & intangibles | $54.98B | $51.67B | $50.22B | $60.95B | — | +6.4% |
| Total assets | $110.95B | $102.25B | $99.94B | $117.45B | — | +8.5% |
| Total current liabilities | $27.28B | $28.69B | $26.39B | $28.66B | — | -4.9% |
| Current debt | $5.52B | $8.09B | $6.08B | $5.88B | — | -31.7% |
| Long-term debt | $27.93B | $21.37B | $18.44B | $20.24B | — | +30.7% |
| Total debt | $35.38B | $31.26B | $26.35B | $27.91B | — | +13.2% |
| Total liabilities | $64.40B | $58.12B | $53.20B | $58.03B | — | +10.8% |
| Retained earnings | — | $46.56B | $49.65B | $63.54B | $70.99B | — |
| Shareholder equity | $46.13B | $44.05B | $46.67B | $59.34B | — | +4.7% |
| Working capital | $3.18B | $1.01B | $4.09B | $8.25B | — | +214.4% |
| Net tangible assets | -$8.85B | -$7.63B | -$3.55B | -$1.60B | — | -16.0% |
| Shares issued | 2.11B | 2.19B | 2.28B | 2.40B | — | -3.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $13.97B | $11.94B | $8.57B | $6.05B | +17.0% |
| Depreciation & amortisation | $5.33B | $6.07B | $8.28B | $6.71B | -12.3% |
| Stock-based compensation | $1.10B | $1.04B | $865.00M | $791.00M | +5.0% |
| Change in working capital | -$1.58B | -$706.00M | -$369.00M | -$796.00M | -123.4% |
| Operating cash flow | $19.14B | $17.62B | $14.46B | $14.24B | +8.7% |
| Capital expenditure | -$3.90B | -$3.81B | -$2.75B | -$2.24B | -2.3% |
| Investing cash flow | -$4.88B | -$7.51B | $5.60B | $1.47B | +35.1% |
| Share buybacks | -$9.21B | -$8.33B | -$8.72B | -$10.65B | -10.6% |
| Dividends paid | -$7.82B | -$7.62B | -$7.25B | -$7.51B | -2.5% |
| Financing cash flow | -$14.87B | -$11.74B | -$14.28B | -$20.56B | -26.6% |
| Free cash flow | $15.24B | $13.80B | $11.71B | $12.00B | +10.4% |
| End cash position | $11.44B | $11.46B | $13.39B | $7.52B | -0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $14.95B | $13.52B | $13.86B | $14.36B | $14.84B | +10.6% |
| Operating revenue | $14.41B | $13.11B | $13.34B | $13.91B | $14.05B | +9.9% |
| Cost of revenue | $3.71B | $3.46B | $3.61B | $3.54B | $3.32B | +7.3% |
| Gross profit | $11.24B | $10.06B | $10.25B | $10.82B | $11.51B | +11.7% |
| Research & development | $2.85B | $2.74B | $3.16B | $2.94B | $2.73B | +3.9% |
| Selling, general & admin | $3.24B | $3.14B | $3.44B | $3.31B | $3.44B | +3.2% |
| Total operating expense | $6.49B | $5.83B | $6.63B | $6.32B | $6.65B | +11.3% |
| Operating income | $4.75B | $4.24B | $3.62B | $4.50B | $4.86B | +12.2% |
| Net interest income | -$479.00M | -$393.00M | -$96.00M | -$301.00M | -$330.00M | -21.9% |
| Pre-tax income | $4.27B | $3.84B | $3.22B | $4.20B | $4.53B | +11.2% |
| Tax provision | $1.01B | $683.00M | $814.00M | $266.00M | $507.00M | +48.2% |
| Net income | $3.26B | $3.16B | $2.41B | $3.93B | $4.04B | +3.4% |
| Net income to common | $3.26B | $3.16B | $2.41B | $3.93B | $4.04B | +3.4% |
| Basic EPS | 1.71 | 1.65 | 1.26 | 2.04 | 2.07 | +3.6% |
| Diluted EPS | 1.71 | 1.65 | 1.25 | 2.02 | 2.06 | +3.6% |
| EBIT | $4.73B | $4.18B | $3.52B | $4.48B | $4.82B | +13.1% |
| EBITDA | $6.13B | $5.41B | $5.07B | $5.84B | $6.08B | +13.3% |
| Basic shares | 1.91B | 1.91B | 1.91B | 1.93B | 1.95B | -0.2% |
| Diluted shares | 1.91B | 1.92B | 1.93B | 1.94B | 1.96B | -0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.62B | $6.88B | $11.44B | $9.56B | $6.66B | — | +10.7% |
| Cash & short-term investments | $7.69B | $6.98B | $11.53B | $9.75B | $7.00B | — | +10.2% |
| Accounts receivable | $9.64B | $9.39B | $8.94B | $8.84B | $9.06B | — | +2.7% |
| Inventory | $6.22B | $6.29B | $6.27B | $6.42B | $6.31B | — | -1.0% |
| Total current assets | $27.35B | $26.61B | $30.46B | $28.20B | $25.94B | — | +2.8% |
| Property, plant & equipment | $12.27B | $12.24B | $12.35B | $11.99B | $11.83B | — | +0.2% |
| Goodwill & intangibles | $68.84B | $67.03B | $54.98B | $54.59B | $54.79B | — | +2.7% |
| Total assets | $122.03B | $118.53B | $110.95B | $107.29B | $104.39B | — | +3.0% |
| Total current liabilities | $31.75B | $31.37B | $27.28B | $32.00B | $31.71B | — | +1.2% |
| Current debt | $9.59B | $7.62B | $5.52B | $7.52B | $8.31B | — | +25.9% |
| Long-term debt | $37.49B | $37.45B | $27.93B | $22.60B | $22.47B | — | +0.1% |
| Total debt | $49.01B | $47.00B | $35.38B | $32.02B | $32.64B | — | +4.3% |
| Total liabilities | $80.09B | $79.61B | $64.40B | $62.54B | $62.34B | — | +0.6% |
| Retained earnings | $39.65B | $37.25B | — | $43.51B | $41.53B | $39.84B | +6.4% |
| Shareholder equity | $41.54B | $38.51B | $46.13B | $44.33B | $41.98B | — | +7.9% |
| Working capital | -$4.40B | -$4.77B | $3.18B | -$3.80B | -$5.78B | — | +7.8% |
| Net tangible assets | -$27.30B | -$28.52B | -$8.85B | -$10.26B | -$12.81B | — | +4.3% |
| Shares issued | 1.90B | 2.03B | 2.11B | 1.92B | 2.07B | — | -6.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $3.26B | $3.16B | $2.40B | $3.93B | $4.02B | — | +3.2% |
| Depreciation & amortisation | $1.40B | $1.23B | $1.55B | $1.36B | $1.26B | — | +14.0% |
| Stock-based compensation | $267.00M | $303.00M | $299.00M | $268.00M | $267.00M | — | -11.9% |
| Change in working capital | $232.00M | -$787.00M | -$1.59B | $1.34B | $442.00M | — | +129.5% |
| Operating cash flow | $5.88B | $3.68B | $2.26B | $6.57B | $6.66B | — | +60.0% |
| Capital expenditure | -$758.00M | -$807.00M | -$1.02B | -$831.00M | -$558.00M | — | +6.1% |
| Investing cash flow | -$3.10B | -$11.74B | -$2.10B | -$860.00M | -$2.24B | — | +73.5% |
| Share buybacks | -$1.20B | -$1.88B | -$1.48B | -$2.30B | -$2.71B | — | +36.1% |
| Dividends paid | -$2.87B | -$6.20B | $0 | — | -$2.48B | -$5.33B | +53.7% |
| Financing cash flow | -$2.02B | $3.58B | $1.68B | -$2.79B | -$5.21B | — | -156.4% |
| Free cash flow | $5.12B | $2.87B | $1.25B | $5.74B | $6.11B | — | +78.6% |
| End cash position | $7.62B | $6.88B | $11.44B | $9.56B | $6.66B | — | +10.7% |
Options analytics
Put / call volume
1.10
Put-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
100.00
-29.0% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
144
Contracts, this expiry
Put volume
158
Contracts, this expiry
Heaviest call OI
220.00
3 contracts
Heaviest put OI
100.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 2.15 | 2.41 | +12.2% |
| Mar 2026 | 2.07 | 1.99 | -3.7% |
| Dec 2025 | 2.00 | 2.03 | +1.3% |
| Sep 2025 | 2.31 | 2.25 | -2.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.24 | 3 | $14.65B | +2.0% |
| Next quarter | 2.22 | 3 | $14.99B | +8.2% |
| Current year | 8.83 | 9 | $57.69B | +1.8% |
| Next year | 9.79 | 10 | $61.39B | +6.4% |
Analyst targets & ownership
Mean target$155.01
High target$185.00
Low target$130.00
Implied upside8.86%
Analyst count11
ConsensusHOLD
Strong buy / Buy3 / 2
Hold6
Sell / Strong sell1 / 0
Held by insiders0.01%
Held by institutions7.27%
Institutions holding1.81K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
143.07
-0.47% from price
SMA 20
141.13
-0.24% from price
SMA 50
149.93
-6.10% from price
SMA 100
150.89
-5.62% from price
SMA 200
150.79
-6.63% from price
EMA 12
142.44
-0.03% from price
EMA 26
144.68
-1.57% from price
EMA 50
147.46
-3.43% from price
RSI (14)
40.2
Neutral
MACD (12,26,9)
-2.24
Hist 0.28
ATR (14)
2.01
1.43% of price
Realised vol 30D
48.8%
Annualised
Bollinger upper
146.49
20, 2σ
Bollinger lower
135.78
20, 2σ
50 / 200 cross
Death
149.93 vs 150.79
Trend bias
Below 200
-6.63%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.33
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
48.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-18.7%
Peak to trough
Max drawdown 5Y
-20.4%
Peak to trough
ATR 14
2.01
1.43% of price
Beta (reported)
0.47
5Y monthly, from filing
Short interest
Shares short
5.20M
Prior 4.99M
Change vs prior
+4.0%
Shorts adding
% of float
0.27%
Normal
% of shares out
0.27%
Against total outstanding
Days to cover
2.2
Liquid
Float
1.86B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 26 | HSBC | UPGRADE | Reduce | Hold |
| Mar 26, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jan 6, 26 | Barclays | UPGRADE | Underweight | Equal-Weight |
| Dec 8, 25 | JP Morgan | UPGRADE | Neutral | Overweight |
| Sep 12, 25 | Goldman Sachs | DOWNGRADE | Neutral | Sell |
| Feb 13, 25 | UBS | DOWNGRADE | Buy | Neutral |
| Nov 19, 24 | Erste Group | DOWNGRADE | Buy | Hold |
| Oct 30, 24 | BMO Capital | MAINTAINED | Market Perform | Market Perform |
| Sep 11, 24 | B of A Securities | DOWNGRADE | Buy | Neutral |
| Sep 5, 24 | Goldman Sachs | DOWNGRADE | Buy | Neutral |
| Sep 3, 24 | Jefferies | DOWNGRADE | Buy | Hold |
| Jul 2, 24 | Jefferies | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate$4.74 / yr
Forward yield3.37%
5-year avg yield3.48%
Payout ratio71.60%
Ex-dividend dateMar 11, 2026
Next pay dateMar 16, 2026
Last split1116:1000
Split dateApr 9, 2019
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-08
Corporate Changes & Voting Matters
6-K · 2026-09-04
Corporate Changes & Voting Matters
6-K · 2026-09-01
Corporate Changes & Voting Matters
6-K · 2026-07-21
Corporate Changes & Voting Matters
6-K · 2026-06-11
Corporate Changes & Voting Matters
6-K · 2026-04-28
Corporate Changes & Voting Matters
6-K · 2026-03-18
Periodic Financial Reports
20-F · 2026-02-04
Headlines
Pacibekitug Market Size, Sales Forecast, and Competitive Analysis - 2034 | Phase III-Ready IL-6 Therapy Targets Major Cardiovascular Growth Opportunities in the 7MM
GlobeNewswire · 16m ago
Novartis (SWX:NOVN) Stock May Trade Below Fair Value As Digital CMC News Lands
Simply Wall St. · 2h ago
Novartis Stocks Stay Flat as $575 Million RNA Bet Opens $7.2 Billion Tail
GuruFocus.com · 13h ago
SAP Puts the Autonomous Enterprise to Work
PR Newswire · 21h ago
Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium
PR Newswire · 23h ago
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Zacks · 2d ago
GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition
Barrons.com · 2d ago
GE HealthCare to Buy Sofie for Nearly $1 Billion to Grow Medical-Imaging Business
The Wall Street Journal · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.